Patent · US Active

Peptide antagonists of the vasopressin-2 receptor

US9631001B2 · kind B2 · utility

0Cited by

1References

13Claims

0Family size

Assignees

COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · FR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
Universität Regensburg · DE
UNIVERSITE DE LIEGE · BE

Inventors

Nicolas Gilles · Mitry-Mory, FR
Denis Servent · Damiette, FR
Loïc Quinton · Strée-lez-Huy, BE
Helen Reinfrank · Neutraubling, DE
Ralph Witzgall · Regensburg, DE
Bernard Mouillac · Montpellier, FR
Christiane Mendre · Argelliers, FR

Key dates

Filing date	Sep 17, 2013
Grant date	Apr 25, 2017
Priority date	—
Expiry date	Sep 17, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a new group of snake venom basic protease inhibitors having vasopressin-2 receptor antagonist activity that can be used in therapy, diagnosis, medical imaging, drug screening and research.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.